WZ4002Mutant-selective EGFR inhibitor(L858R,T790M), irreversible and potent CAS# 1213269-23-8 |
- Dacomitinib (PF299804, PF299)
Catalog No.:BCC3683
CAS No.:1110813-31-4
- AG-1478
Catalog No.:BCC3717
CAS No.:153436-53-4
- OSI-420
Catalog No.:BCC4472
CAS No.:183320-51-6
- Gefitinib hydrochloride
Catalog No.:BCC1591
CAS No.:184475-55-6
- Lapatinib Ditosylate
Catalog No.:BCC2083
CAS No.:388082-78-8
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 1213269-23-8 | SDF | Download SDF |
PubChem ID | 44607530 | Appearance | Powder |
Formula | C25H27ClN6O3 | M.Wt | 495.0 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | WZ-4002;WZ 4002 | ||
Solubility | DMSO : ≥ 100 mg/mL (202.03 mM) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | N-[3-[5-chloro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]oxyphenyl]prop-2-enamide | ||
SMILES | CN1CCN(CC1)C2=CC(=C(C=C2)NC3=NC=C(C(=N3)OC4=CC=CC(=C4)NC(=O)C=C)Cl)OC | ||
Standard InChIKey | ITTRLTNMFYIYPA-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C25H27ClN6O3/c1-4-23(33)28-17-6-5-7-19(14-17)35-24-20(26)16-27-25(30-24)29-21-9-8-18(15-22(21)34-3)32-12-10-31(2)11-13-32/h4-9,14-16H,1,10-13H2,2-3H3,(H,28,33)(H,27,29,30) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | WZ4002 is a novel, mutant-selective inhibitor of EGFR for EGFR(L858R)/(T790M) with IC50 of 2 nM/8 nM. | |||||
Targets | EGFRL858R | EGFRL858R/T790M | ||||
IC50 | 2 nM | 8 nM |
WZ4002 Dilution Calculator
WZ4002 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.0202 mL | 10.101 mL | 20.202 mL | 40.404 mL | 50.5051 mL |
5 mM | 0.404 mL | 2.0202 mL | 4.0404 mL | 8.0808 mL | 10.101 mL |
10 mM | 0.202 mL | 1.0101 mL | 2.0202 mL | 4.0404 mL | 5.0505 mL |
50 mM | 0.0404 mL | 0.202 mL | 0.404 mL | 0.8081 mL | 1.0101 mL |
100 mM | 0.0202 mL | 0.101 mL | 0.202 mL | 0.404 mL | 0.5051 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Abstract
Due to the ability of WZ4002, an EGFR TKI, to suppress phosphorylated EGFR in both H1975 and HCC827 cells, the combination of WZ4002, ABT-263 and TSA almost completely eradicated both the suspended cell lines.
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
WZ4002 is a novel mutant-selective epidermal growth factor receptor (EGFR) kinase inhibitor that potently and irreversibly suppresses the ATP-dependent auto-phosphorylation of both wild-type EGFR and EGFR mutants, including EGFR delE746_A750/T790M, EGFR L858R/T790M, EGFR T790M, EGFR delE746_A750 and EGFR L858R, with inhibition constant Ki of 13.6 nM, 1.8 nM, 4 nM, 5 nM, 3.9 nM and 8.5 nM respectively. Although WZ4002 is actively against EGFR mutants rather than wild-type EGFR at lower concentrations resulting in less toxicity in normal tissues, wild-type EGFR is susceptible to higher concentrations of WZ4002 as well as prolonged administration of WZ4002, especially in tissues where it accumulates.
References:
[1]Lee HJ, Schaefer G, Heffron TP, Shao L, Ye X, Sideris S, Malek S, Chan E, Merchant M, La H, Ubhayakar S, Yauch RL, Pirazzoli V, Politi K, Settleman J. Noncovalent wild-type-sparing inhibitors of EGFR T790M. Cancer Discov. 2013 Feb;3(2):168-81. doi: 10.1158/2159-8290.CD-12-0357. Epub 2012 Dec 10.
[2]Zhou W, Ercan D, Chen L, Yun CH, Li D, Capelletti M, Cortot AB, Chirieac L, Iacob RE, Padera R, Engen JR, Wong KK, Eck MJ, Gray NS, Jänne PA. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature. 2009 Dec 24;462(7276):1070-4. doi: 10.1038/nature08622.
[3]Zannetti A, Iommelli F, Speranza A, Salvatore M, Del Vecchio S. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer. J Nucl Med. 2012 Mar;53(3):443-50. doi: 10.2967/jnumed.111.096503. Epub 2012 Feb 13.
- 1-Hydroxybisabola-2,10-dien-4-one
Catalog No.:BCN7297
CAS No.:1213251-45-6
- RWJ 21757
Catalog No.:BCC7460
CAS No.:121288-39-9
- Alendronate
Catalog No.:BCC4885
CAS No.:121268-17-5
- ICI 204,448 hydrochloride
Catalog No.:BCC6806
CAS No.:121264-04-8
- Calphostin C
Catalog No.:BCC7131
CAS No.:121263-19-2
- Secodihydro-hydramicromelin B
Catalog No.:BCN4783
CAS No.:1212148-58-7
- [Ala1,3,11,15]-Endothelin
Catalog No.:BCC5731
CAS No.:121204-87-3
- TC-N 1752
Catalog No.:BCC6179
CAS No.:1211866-85-1
- Rauvoyunine C
Catalog No.:BCN4833
CAS No.:1211543-01-9
- LEE011 hydrochloride
Catalog No.:BCC4101
CAS No.:1211443-80-9
- LEE011
Catalog No.:BCC3926
CAS No.:1211441-98-3
- Cefprozil hydrate
Catalog No.:BCC4951
CAS No.:121123-17-9
- Fmoc-Glu-OH
Catalog No.:BCC3489
CAS No.:121343-82-6
- SR 33805 oxalate
Catalog No.:BCC7181
CAS No.:121346-33-6
- Bernardioside A
Catalog No.:BCN7862
CAS No.:121368-52-3
- N6-Benzyladenine
Catalog No.:BCC9076
CAS No.:1214-39-7
- POM 1
Catalog No.:BCC7454
CAS No.:12141-67-2
- WZ3146
Catalog No.:BCC4004
CAS No.:1214265-56-1
- WZ8040
Catalog No.:BCC1075
CAS No.:1214265-57-2
- WZ4003
Catalog No.:BCC4363
CAS No.:1214265-58-3
- Ajugapantin A
Catalog No.:BCN3663
CAS No.:121449-67-0
- Daclatasvir (BMS-790052)
Catalog No.:BCC2533
CAS No.:1214735-16-6
- 5-Benzyloxyindole
Catalog No.:BCC8742
CAS No.:1215-59-4
- PF-04991532
Catalog No.:BCC8094
CAS No.:1215197-37-7
WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors.[Pubmed:22157722]
Lab Invest. 2012 Mar;92(3):371-83.
Src has a role in the anoikis resistance in lung adenocarcinomas. We focused on two epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma cell lines, HCC827 (E746-A750 deletion) and H1975 (L858R+T790M), in suspension to elucidate whether suspended lung adenocarcinoma cells are eradicated by long-term treatment with Src tyrosine kinase inhibitors (TKIs). We also examined metastasis-positive lymph nodes from 16 EGFR-mutant lung adenocarcinoma patients for immunohistochemical expression of mutant-specific EGFR. Almost all suspended HCC827 cells underwent apoptosis after 144 h of combination treatment with AZD0530, trichostatin A (TSA), and ABT-263, whereas many suspended H1975 cells survived the treatment. AZD0530 is a Src TKI, TSA is a histone deacetylase inhibitor, and ABT-263 is a Bcl-2 inhibitor. During the therapy, the phosphorylation of EGFR decreased in HCC827 cells and remained stable in H1975 cells. The phosphorylated EGFR of Src TKI-resistant H1975 cells, as well as HCC827 cells, was completely suppressed by the third generation EGFR TKI, WZ4002. Consequently, both the suspended cell lines were almost completely eradicated within 144 h, with the combined therapy of WZ4002, ABT-263, and TSA. Interestingly, treated suspended cells underwent apoptosis to a greater extent than did adherent cells. Intrasinus floating lung adenocarcinoma cells in the lymph nodes expressed a mutant-specific EGFR. These findings suggest that suspended EGFR-mutant lung adenocarcinoma cells depend significantly more on EGFR activation for survival than attached cells do. The tumor cells circulating in vessels, which express mutant-specific EGFR, would be highly susceptible to the combination therapy of WZ4002, ABT-263, and TSA.